Patents Examined by Jane Zara
  • Patent number: 9624492
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: April 18, 2017
    Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventor: Joseph S. Zakrzewski
  • Patent number: 9617581
    Abstract: A method of generating a gene expression profile of noncoding regulatory RNA (ncRNA; e.g. a microRNA) in a cell in vivo, is carried out by: (a) partitioning from a cell at least one mRNA-protein (RNP) complex, the RNP complex comprising: (i) an RNA binding protein (RNABP) or RNA associated protein, (ii) at least one mRNA bound to or associated with said protein, and (iii) at least one ncRNA bound to or associated with said protein, and then (b) identifying at least one ncRNA in-at least one RNP complex, thereby to produce a gene expression profile comprising the identity of an ncRNA in an RNP complex.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: April 11, 2017
    Assignee: Duke University
    Inventors: Jack D. Keene, Patrick J. Lager
  • Patent number: 9611511
    Abstract: The present invention relates to single polynucleotides or sets of polynucleotides for detecting single miRNAs or sets of miRNAs for diagnosing and/or prognosing of an acute coronary syndrome in a blood sample from a human. Further, the present invention relates to means for diagnosing and/or prognosing of an acute coronary syndrome comprising said polynucleotides or sets of polynucleotides. Furthermore, the present invention relates to a method for diagnosing and/or prognosing of an acute coronary syndrome based on the determination of expression profiles of single miRNAs or sets of miRNAs representative for an acute coronary syndrome compared to a reference. In addition, the present invention relates to a kit for diagnosing and/or prognosing of an acute coronary syndrome comprising means for determining expression profiles of single miRNAs or sets of miRNAs representative for an acute coronary syndrome and at least one reference.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: April 4, 2017
    Assignee: COMPREHENSIVE BIOMARKER CENTER GMBH
    Inventors: Andreas Keller, Peer F. Stähler, Markus Beier, Benjamin Meder, Hugo A. Katus, Wolfgang Rottbauer
  • Patent number: 9605260
    Abstract: Provided herein are compositions and methods for the alteration of neuronal methylation by synthetic piRNAs or by alteration of piRNA function. Such alterations find use in the regulation and control of neural gene expression and concomitant neural functions. Further provided herein are systems and methods for the identification of target sites for regulation by piRNAs.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 28, 2017
    Assignee: IBIS BIOSCIENCES, INC.
    Inventors: David J. Ecker, Todd P. Michael, Lendell L. Cummins, Mark W. Eshoo, Stanley T. Motley, Danny M. Chou
  • Patent number: 9598698
    Abstract: The present invention relates to methods for co-silencing expression of genes in a filamentous fungal strain by transitive RNA interference. The present invention also relates to methods for identifying a gene encoding a biological substance of interest.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: March 21, 2017
    Assignee: Novozymes A/S
    Inventors: Howard Brody, Evee Ricacho, Hiroshi Teramoto
  • Patent number: 9597346
    Abstract: The present invention provides a method of reducing levels of at least one target protein in a cell. The cell is contacted with a first agent and a second agent. The first agent reduces synthesis of the target protein, e.g., by reducing levels of the mRNA of the target protein or inhibits translation of the mRNA. The second agent accelerates degradation of the target protein. The first agent may contact the cell before, after or simultaneously with the second agent. The first agent and the second agent may be in separate delivery vehicles, or in a single delivery vehicle. The first agent may be an RNAi (RNA interference) molecule, such as a small interfering RNA (siRNA), a small hairpin RNA (shRNA) or a microRNA (miRNA). The second agent may be a chimeric polypeptide containing a ubiquitin ligase polypeptide and a target protein interacting domain. The ubiquitin ligase polypeptide can be an E3 ubiquitin ligase, including, but not limited to, an SCF polypeptide, a HECT polypeptide and a UBR1 polypeptide.
    Type: Grant
    Filed: January 17, 2011
    Date of Patent: March 21, 2017
    Assignee: Cornell University
    Inventor: Pengbo Zhou
  • Patent number: 9598734
    Abstract: The present invention features methods, devices, and kits for predicting the sensitivity of a patient to a compound or medical treatment. The invention also features methods for identifying biomarkers, the expression of which correlates to treatment sensitivity or resistance within a patient population or subpopulation.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: March 21, 2017
    Assignee: Medical Prognosis Institute A/S
    Inventor: Steen Knudsen
  • Patent number: 9592301
    Abstract: A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: March 14, 2017
    Inventors: Kenneth Michael Hargreaves, John Gordon Bruno
  • Patent number: 9587239
    Abstract: The invention encompasses methods and kits used in the detection of invasive glioblastoma based upon the expression of NHERF-1. The methods and kits also allow prediction of disease outcome as well as therapeutic outcome.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: March 7, 2017
    Assignee: The Translational Genomics Research Institute
    Inventors: Kerri L. Kislin, Michael Edward Berens
  • Patent number: 9587240
    Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary (antisense) RNA strand having a 1 to 4 nucleotide overhang at the 3?-end and a blunt 5?-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages (i.e., less than 5 milligrams, preferably less than 25 micrograms, per kg body weight per day). The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: March 7, 2017
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer, Sylvia Limmer, Philipp Hadwiger
  • Patent number: 9580713
    Abstract: Disclosed are compounds, compositions, and methods relating to fluoride aptamers, fluoride-responsive riboswitches, fluoride-regulated expression constructs, fluoride transporters, nucleic acids encoding fluoride transporters, expression constructs encoding fluoride transporters, and cells containing or including any combination of these.
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: February 28, 2017
    Assignee: Yale University
    Inventors: Ronald Breaker, Jenny Baker, Narasimhan Sudarsan, Zasha Weinberg, Adam Roth, Tyler Ames, James Nelson
  • Patent number: 9572891
    Abstract: Oligonucleotide conjugates, where an oligonucleotide is covalently attached to an aromatic system, are provided. In particular embodiments the oligonucleotide is complementary to the RNA component of human telomerase and is covalently attached to a nucleobase via an optional linker. The conjugates inhibit telomerase enzyme activity.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: February 21, 2017
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Krisztina Pongracz, Richard L. Tolman, Gregg B. Morin
  • Patent number: 9566295
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: February 14, 2017
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • Patent number: 9567592
    Abstract: In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector (FIG. 1A). Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell. In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle. In yet a further aspect, the invention provides methods for expression of a small RNA molecule within a cell, such as an siRNA capable of downregulating CCR5, wherein expression of the small RNA molecule is relatively non-cytotoxic to the cell. The invention also includes small RNA molecules, such as an siRNA capable of downregulating CCR5, that are relatively non-cytotoxic to cells.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: February 14, 2017
    Assignees: California Institute of Technology, The Regents of the University of California
    Inventors: Carlos Lois-Caballe, David Baltimore, Xiao-Feng Qin, Irvin S. Y. Chen, Dong Sung An
  • Patent number: 9567580
    Abstract: Embodiments of the inventions relate to modulating NFAT activity, modulating store-operated Ca2+ entry into a cell and treating and/or preventing hyperactivity or inappropriate immune response by inhibiting the expression or activities of septin 4 (SEPT 4) and septin 5 (SEPT 5) proteins involved in the calcineurin/NFAT axis and T-cell activation.
    Type: Grant
    Filed: October 10, 2011
    Date of Patent: February 14, 2017
    Inventors: Anjana Rao, Patrick Hogan, Sonia Sharma
  • Patent number: 9562233
    Abstract: The invention provides isolated soluble endoglin polypeptides, nucleic acids encoding soluble endoglin polypeptides, antibodies that specifically bind soluble endoglin polypeptides, and kits containing these materials. The invention also provides methods for treating or decreasing the likelihood of developing a soluble endoglin-mediated disorder in a subject requiring the administration of an agent capable of reducing the expression or biological activity of a soluble endoglin polypeptide and methods for treating or decreasing the likelihood of developing a soluble endoglin-preventive disorder in a subject requiring the administration of a soluble endoglin polypeptide or a nucleic acid encoding the soluble endoglin polypeptide. The invention further provides methods for the diagnosis of a soluble endoglin-mediated disorder or a soluble endoglin-preventive disorder and methods for identifying a compound to treat a soluble endoglin-mediated or a soluble endoglin-preventive disorder.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: February 7, 2017
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Mourad Topors
  • Patent number: 9562228
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing MYC target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: February 7, 2017
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Patent number: 9556431
    Abstract: The present invention relates to certain novel shRNA molecules and methods of use thereof. According to certain embodiments of the present invention, methods for reducing the expression level of a target gene are provided. Such methods generally comprise providing a cell with one or more precursor nucleic acid sequences that encode two or more RNA molecules. A first RNA molecule comprises a double stranded sequence, which includes a guide strand sequence that is complementary to a portion of an mRNA transcript encoded by the target gene. In addition, a second RNA molecule comprises a second double stranded sequence, which includes a second guide strand sequence that is partially complementary to a portion of the mRNA transcript encoded by the target gene. Preferably, the second guide strand sequence comprises one or more bases that are mismatched with a nucleic acid sequence of the mRNA transcript encoded by the target gene.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 31, 2017
    Assignee: Strike Bio, Inc.
    Inventor: Donald Rao
  • Patent number: 9551011
    Abstract: The invention provides methods and compositions for the expression of small RNA molecules within a cell using a lentiviral vector. The methods can be used to express doubles stranded RNA complexes. Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell, which are capable of down regulating the expression of a target gene through RNA interference. A variety of cells can be treated according to the methods of the invention including embryos, embryogenic stem cells, allowing for the generation of transgenic animals or animals constituted partly by the transduced cells that have a specific gene or a group of genes down regulated.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: January 24, 2017
    Assignee: California Institute of Technology
    Inventors: Carlos Lois-Caballe, David Baltimore, Xiao-Feng Qin
  • Patent number: 9545418
    Abstract: The invention includes compositions and methods of treatment of cancers susceptible to treatment with nucleotide analog chemotherapeutic agent, including cancers in which nucleotide analog resistant tumors have developed, including identifying a subject having cancer susceptible to treatment with a nucleotide analog chemotherapeutic agent and a mitotic disruptor/polo-like kinase (Plk) pathway inhibitor to a subject; and monitoring the subject for a reduction of stabilization of at least one sign or symptom of cancer.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: January 17, 2017
    Assignee: The Johns Hopkins University
    Inventors: Antonio Jimeno, Manuel Medina Hidalgo